is critical, however, as evaluation, treatment, and prognosis for the two conditions are divergent. Improved techniques to separate these two entities are required.
We previously performed a study comparing clinical, endoscopic, and histological features of EoE and GERD patients ( 23 ) . Although no individual feature was pathognomic, on multivariable analysis, a set of factors independently distinguished EoE from GERD and had substantial utility for diagnosis of EoE as measured with receiver operator characteristic (ROC) curve analysis. However, this study was retrospective, encompassed a time frame when features of EoE might not have been universally recognized, did not assess patients with symptoms of dysphagia who did not have EoE, and included full histopathological data in the model, which limited clinical utility.
Th e aim of the present study was to determine prospectively whether a set of clinical and endoscopic features could be used as a prediction tool to distinguish patients with EoE from patients with GERD-or dysphagia-predominant symptoms not caused by EoE without obtaining esophageal biopsies. We hypothesized that a multivariable model would diff erentiate EoE cases from non-EoE controls with a high degree of accuracy as measured by the area under the ROC curve (AUC).
METHODS

Study design and patient population
Th is was a prospective study performed at University of North Carolina from July 2011 through December 2013. Consecutive adult patients (age 18-80 years) referred for outpatient esophagogastroduodenoscopy were eligible for recruitment if they had symptoms of esophageal dysfunction, such as dysphagia, food impaction, heartburn, refl ux, or chest pain, that could suggest EoE clinically. Subjects were excluded if they had a known (prevalent) diagnosis of EoE or a diff erent eosinophilic gastrointestinal disorder, gastrointestinal bleeding, active anticoagulation, known esophageal cancer, prior esophageal surgery, known esophageal varices, medical instability or multiple comorbidities precluding enrollment in the clinical opinion of the endoscopist, or inability to read or understand the consent form. Subjects provided informed consent and were enrolled prior to the endoscopy. Endoscopy could be performed by any of the gastroenterologists at University of North Carolina. A total of 15 attending physicians performed study endoscopies; the majority (73%) were performed by a single endoscopist (E.S.D.). Th is study was approved by the University of North Carolina Institutional Review Board and registered on clinicaltrials.gov (NCT 01988285).
Case defi nitions and clinical data
EoE cases were diagnosed per consensus guidelines (1) (2) (3) . Th ey were required to have at least one typical symptom of esophageal dysfunction, an esophageal biopsy demonstrating ≥15 eosinophils per high-power fi eld (eos/hpf) aft er an 8-week trial of a protonpump inhibitor (PPI; 20-40 mg twice daily of any of the available agents, prescribed at the discretion of the clinician), and other causes of esophageal eosinophilia excluded. Accordingly, baseline data for the EoE cases were obtained aft er the PPI trial and at the time of the confi rmatory endoscopy but prior to knowledge of the biopsy results and before any EoE-specifi c treatment was prescribed. Subjects who were enrolled and found to have esophageal eosinophilia but who were not on a PPI were prescribed a high-dose PPI trial. If symptoms and esophageal eosinophilia ≥15 eos/hpf persisted, EoE was diagnosed and they were included in the study. If symptoms and eosinophilia resolved (<15 eos/hpf), they were diagnosed with PPI-responsive esophageal eosinophilia (PPI-REE) and were not included in this analysis. PPI-REE was excluded for several reasons. First, because the major aim of the study was to predict EoE case status at endoscopy and prior to biopsy, we used the consensus diagnostic guidelines as the gold standard, and these guidelines require exclusion of PPI-REE. Second, previous work by us and others compared EoE and PPI-REE subjects and found that clinical, endoscopic, and histological features did not distinguish these groups (24) (25) (26) (27) (28) . Finally, pH testing was not a component of this study, as it has not been shown to predict PPI-REE status or refl ux as a cause of esophageal eosinophilia ( 25, 26, 29 ) .
Non-EoE controls were subjects with symptoms of esophageal dysfunction as noted above who, aft er endoscopy and biopsy, did not meet clinical and histological criteria for EoE. PPI use was not proscribed in this group and was at the discretion of the referring provider. Controls with dysphagia-and GERD-predominant symptoms (i.e., heartburn, refl ux, chest pain) without consideration of clinical PPI response were recruited in equal numbers to allow for secondary analyses as noted below. Th is distinction was based on symptoms at the time of presentation for endoscopy and represents a control group previously used for such studies, given that they are at risk for EoE and would otherwise meet disease defi nition if they had accompanying appropriate histological fi ndings ( 30 ) .
Standardized case report forms and a prospectively administered questionnaire were used to collect clinical data, including demographics, medical history, symptoms, allergic conditions, indications for endoscopy, endoscopic fi ndings, and fi nal diagnoses. Food allergies were provided by patient self-report and could refl ect either overt allergic reactions or sensitization. During endoscopy, esophageal biopsies for research use were obtained (two from the proximal, one from the mid, and two from the distal esophagus) to maximize EoE diagnostic sensitivity ( 31, 32 ) . Gastric and duodenal biopsies were also collected for research purposes to exclude concomitant eosinophilic gastroenteritis. Additional clinical biopsies were taken as indicated at the discretion of the endoscopist.
Th e study pathologists quantifi ed the esophageal eosinophil counts using our previously validated methodology ( 33 ) . In brief, slides were masked to case/control status, digitized, and reviewed with Aperio ImageScope (Aperio Technologies, Vista, CA). Five microscopic fi elds from each of the fi ve biopsies were examined to determine the maximum eosinophil density (eosinophils/mm 2 (eos/mm 2 )). In order to compare results with prior studies, eosinophil density was converted to an eosinophil count (eos/hpf) using a hpf size of 0.24 mm 2 , the most commonly reported fi eld size in
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EoE Clinical Prediction Tool the literature ( 5 ) . In addition to eosinophilic counts, associated histological fi ndings were also recorded. Th ese included the presence of eosinophilic microabscesses (clusters of ≥4 eosinophils), eosinophil degranulation, basal layer hyperplasia (when evaluable in properly oriented specimens), spongiosis, and lamina propria fi brosis (if adequate subepithelial stroma was present) ( 32, 34 ) .
Statistical analysis
Distributions of all clinical, endoscopic, and histological variables of interest were summarized and described. To compare the EoE cases and non-EoE controls, we used Chi-square for categorical variables and t -tests or Wilcoxon rank-sum test for continuous variables as appropriate for bivariate analysis.
Predictive models based on beta values derived from our previous study population of EoE cases and GERD controls ( 23 ) were generated and applied to the current prospectively recruited independent population. In brief, the prior study identifi ed a number of factors on multivariate analysis that predicted EoE case status. Th e primary model of interest that we examined in the present study contained clinical and endoscopic, but no histologicl, data, so that EoE case status could be predicted without esophageal biopsy. Beta values and the associated ROC AUC data derived for this model from the data set from the prior study are listed in Supplementary Table S1 online. Other models of secondary interest included:
(1) a model with full clinical, endoscopic, and histological data; (2) a model that did not contain the dysphagia and eosinophil count components of the EoE disease defi nition; and (3) a model with only clinical, but no endoscopic or histological, data. Th ese beta values and AUC results from the prior data set are listed in Supplementary Table S2 .
Th ese prior beta values were then used to construct a multivariate logistic regression model to predict EoE case status in the present study population. Diagnosis of EoE by the consensus guidelines was the gold standard. ROC curves were constructed and AUCs were calculated to determine the utility of the models. Th e AUCs were further contextualized by calculating the sensitivity, specifi city, positive and negative predictive values, and accuracy. For the primary analysis, all non-EoE controls comprised a single group. Several a priori secondary analyses were also performed. Th e models were reanalyzed fi rst limiting the non-EoE control group to those with dysphagia-predominant symptoms and then to those with GERD-predominant symptoms. Th ey were also reanalyzed limiting the control group to those subjects with an elevated eosinophil count at the ≥7 eos/hpf, and then also at the ≥10 eos/hpf levels. Th is allowed us to focus on the group of subjects for whom there would be the most diagnostic confusion. Finally, these analyses were also performed with the models of secondary interest.
Th e planned ROC analysis for the primary analysis determined the necessary sample size. By enrolling at least 60 EoE cases and 120 controls (half with dysphagia-predominant and half with GERD-predominant symptoms), we would have >80% power to detect a true AUC value of >0.90, a highly clinically relevant test performance level ( 35, 36 ) . All analyses were performed with Stata version 9 (Statacorp, College Station, TX).
RESULTS
Patient fl ow and characteristics
Aft er screening 586 subjects referred for outpatient upper endoscopy, 276 were enrolled, yielding 81 EoE cases and 144 non-EoE controls (70 with dysphagia-predominant and 74 with GERDpredominant symptoms); 51 patients with either PPI-REE or a clinically indeterminant phenotype were not analyzed for the purposes of this study ( Figure 1 ).
Th ere were clinical diff erences between the EoE and control groups ( Table 1 ). EoE cases were younger (38 vs. 52 years; P <0.001), more likely to be male (60 vs. 38%; P =0.001) and white (93 vs. 82%; P =0.03), and almost all had dysphagia (98%). Rates of atopy were high in both the EoE and control groups (69 vs. 58%; P =0.09), though food allergies were more common in EoE (43 vs. 15%; P <0.001). Common diagnoses in the control group included GERD (47%), esophageal stricture or Schatzki's ring (18%), functional disorders (17%), and esophageal dysmotility (13%). Additionally, while all of the EoE patients were on twice daily therapy at enrollment, 97 of controls (67%) were on PPI, of whom 58 (40%) were on twice daily dosing.
Th ere were also multiple endoscopic and histological differences between the two groups ( Table 2 ). Very few (4%) of the endoscopic exams were normal in EoE cases. As would be expected in an EoE group, rings (78 vs. 10%), furrows (86 vs. 6%), and plaques (47 vs. 3%) were more common ( P <0.001 for all). Figure 1 . Patient fl ow and enrollment in this study. Of the 261 who were ineligible, 61 had non-esophageal symptoms (i.e., abdominal pain, diarrhea, weight loss, etc), 23 had anemia or gastrointestinal (GI) bleed, 24 had a malignancy, 36 had prior upper gastrointestinal surgery, 9 had known esophageal dysmotility, 51 had known causes of their symptoms and were undergoing therapeutic endoscopy (i.e., prior esophageal stricture; treatment of Barrett's esophagus, etc), and 57 had medical contraindications (varices, coagulopathy, multiple medical comorbidities, etc). Of the 15 who were not classifi ed, 4 had prevalent eosinophilic esophagitis (EoE), 2 had a new diagnosis of eosinophilic gastroenteritis, 2 had a new diagnosis of esophageal cancer, and 7 did not complete a proton-pump inhibitor (PPI) trial to complete the EoE diagnostic algorithm during the study time frame. PPI-REE, PPI-responsive esophageal eosinophilia.
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In contrast, hiatal hernias were less common in the EoE group (14 vs. 54%; P <0.001). Stricture and dilation rates were comparable between the two groups. On histology, the mean eosinophil counts for the cases and controls were 141±119 eos/hpf and 3±6 eos/hpf, respectively ( P <0.001). Associated histological fi ndings, including eosinophil degranulation, microabscesses, basal zone hyperplasia, spongiosis, and lamina propria fi brosis, were more common in the EoE cases.
Predictive modeling
For the primary predictive model analysis (clinical and endoscopic, but no histological, data, so that EoE case status could be predicted without esophageal biopsy), we used the beta values derived from an independent patient population in our prior study (see Supplementary Table S1 ) ( 23 ) . Th e variables included in this model were age, sex, dysphagia, food allergy, rings, furrows, plaques, and hiatal hernia. When these were applied to the prospectively enrolled patient population in the present study, the AUC of the predictive model was 0.944 ( Figure 2 ). Th e model correctly classifi ed 92% of subjects, with a sensitivity of 84%, specifi city of 97%, and positive and negative predictive values of 93 and 91%, respectively ( Table 3 ) . On sub-analysis, the model performed similarly well. Th e AUC was 0.948 for the GERD-predominant control sub-group, 0.940 for the dysphagia-predominant controls, 0.892 for controls with ≥10 eos/hpf, and 0.905 for controls with ≥7 eos/hpf. Similar results were also noted aft er stratifying the control group for baseline PPI status (for PPI users, AUC=0.944; for non-PPI users, AUC=0.965).
Th e analysis of the secondary models of interest also showed similar results. Th e beta values and variables used for these models are listed in Supplementary Table S2 , and ROC curves are displayed in Supplementary Figure . For the model with full clinical, endoscopic, and histological data, the AUC was 0.981. For the model that did not contain the dysphagia and eosinophil count components of the EoE disease defi nition, the AUC was 0.973. For the model with only clinical, but no endoscopic or histological, data, the AUC was not as good at 0.862. Even though dysphagia was a strong factor in all of the models, there was a clinically and statistically signifi cant gain in the predictive power as measured by the AUC between the model of clinical factors alone and our primary model of clinical and endoscopic factors ( P <0.01). Th is is refl ected by an increase in the proportion of EoE cases correctly classifi ed from 76% to 92%.
DISCUSSION
Despite publication of consensus diagnostic criteria for EoE ( 1-3 ), there are no pathognomic symptoms or signs of the disease, and therefore EoE remains challenging to distinguish from other causes of esophageal eosinophilia, particularly GERD, both before and aft er esophageal biopsy ( 5,10,16,18,23 ). Our previous work identifi ed a set of clinical, endoscopic, and histological features, that, when taken together, were highly predictive of EoE case status ( 23 ) . However, the methodology of that study was limited by its retrospective nature and requirement for full biopsy information.
Th e present prospective study aimed to validate a set of clinical and endoscopic features that could distinguish EoE from non-EoE controls with symptoms of esophageal dysfunction, including symptoms of dysphagia and GERD, without esophageal biopsy by using previously derived beta values and applying them to a newly recruited independent population. We found that eight easily obtainable measures, including younger age, male sex, presence of dysphagia and food allergies, presence of esophageal rings, furrows, and plaques, and lack a hiatal hernia, predicted EoE diagnosis with a very high degree of accuracy. Th e results held on additional analyses examining dysphagia-and GERD-predominant controls and in controls with elevated eosinophil counts not owing to EoE. Moreover, we also validated a highly accurate model that could be used when full histological data are available. Taken together, these models have a high degree of clinical utility, both to minimize the need for biopsy in low-yield patients and to help distinguish EoE from other clinical conditions when there is a diagnostic conundrum. Th ere has been intense interest in methods to distinguish EoE from GERD, including analysis of tissue biomarkers ( 20, 22, (37) (38) (39) (40) (41) (42) (43) , non-invasive biomarkers (44) (45) (46) (47) , and most recently, genetic expression profi ling ( 48 ) . Although there have also been recent eff orts to validate symptom and quality-of-life measures (49) (50) (51) (52) (53) , the goal of these investigations has not been to use the symptom scores to diagnose EoE per se . Th ere have been only a few prior Receiver operating characteristic curve for predicting eosinophilic esophagitis case status prior to esophageal biopsy using consensus guidelines as the gold standard. The dotted orange line represents a test that performs no better than chance, which by defi nition has an area under the curve (AUC) of 0.5. For this fi gure, the primary model of interest with clinical and endoscopic, but no histological features, was used. Dellon et al.
similar to our prior study ( 23 ) , they generated a predictive model containing six characteristics-sex, dysphagia, chest pain/heartburn, food impaction, furrows, and plaques-which was able to distinguish EoE from GERD with an AUC of 0.858. With the exception of the study by Aceves et al. ( 54 ) , the others have been retrospective, and none have attempted to validate the fi ndings in an independent population. In this study, we present a clinically relevant predictive model. Being able to recognize patients with symptoms of esophageal dysfunction who are most likely to have EoE, as well as those in whom there is a very low likelihood of EoE, based on clinical and endoscopic factors alone, allows a clinical decision to be made as to whether to obtain an esophageal biopsy. Several prospective studies have shown that esophageal eosinophilia or EoE will be found in up to 3-7% of patients undergoing endoscopy for any reason ( 57, 58 ) , in up to 23% undergoing endoscopy for dysphagia ( 24, (59) (60) (61) , and in 1-8% undergoing endoscopy for PPI-refractory heartburn symptoms (11) (12) (13) (14) 62 ) . Because of this, current guidelines recommend obtaining esophageal biopsies in all patients with dysphagia to assess for EoE, as well considering biopsy in patients with PPI-refractory GERD ( 2, 3, 63 ) . In such a paradigm, there will be far more negative than positive biopsies, particularly in patients with GERD-predominant symptoms. In one analysis, the prevalence of EoE in heartburn patients had to be at least 8%, the top of the reported range, for biopsy to be cost-eff ective ( 64 ) . Moreover, a recent study of shows EoE health-care-related costs are approaching $1 billion annually, a remarkable amount for a relatively uncommon disease ( 65 ) . Th erefore, it is imperative to minimize costs when the biopsy yield is low. Our study provides a model that can do just that. Because of the very high specifi city and negative predictive value, it can accurately identify patients unlikely to have EoE and therefore not require esophageal biopsy. To aid in this process, we have created an on-line calculator that can be used at the point-of-care to provide the probability of an EoE diagnosis ( https://gicenter.med.unc.edu/cedas/eoe_clinical_ calculator.html ).
Th is study does have limitations. We did not use validated measures to characterize severity of symptoms or endoscopic fi ndings. Although those measures are now available ( 49,50,66 ), they did not exist when this study was designed. With the modeling strategy that we employed, only the presence or absence of symptoms and endoscopic signs was required, a metric that is easy to use clinically. Given the excellent performance characteristics of the model, it is unlikely that more complicated assessment of symptom severity would have markedly improved its performance. Second, we did not analyze patients with PPI-REE. Th e overall aim of this study was to distinguish EoE from GERD and other esophageal conditions, and we and others have previously shown that clinical and endoscopic characteristics do not distinguish EoE from PPI-REE ( 24-28 ), so we did not repeat that analysis here. We would emphasize, however, that these predictive models are most appropriately used for patients aft er a PPI trial. Related to this, two-thirds of controls were on PPI. Although there was no way to know whether a patient with GERD symptoms on PPI who had an endoscopy and normal biopsies had prior esophageal eosinophilia, we suspect that this type of misclassifi cation would be rare and, if present, would have biased the results towards the null. Th ird, this was an adult population, so we cannot comment on whether the same factors would have utility in a pediatric population. However, because we have provided the beta values from our results, it would be possible to assess the utility of this model in an independent pediatric population. Finally, we did not perform standardized food allergy testing in this patient population. Th e food allergy variable in the model relies on patient self-report and could include either overt food allergies or food sensitizations. However, our dichotomous patient self-report mimics clinical practice by allowing a practitioner to fi ll in the needed data for the model aft er asking a simple yes/no question.
Th is study also has a number of strengths. It is the largest prospective study to assess a clinical predictive tool for EoE. It applied beta values developed from a prior study population to validate the results in the present independent subject group. Th e screening and enrollment strategy was comprehensive and focused on a clinically relevant population, patients undergoing endoscopy for symptoms of esophageal dysfunction, from which the majority of EoE cases come, and in whom the vast majority of diffi culty in making an EoE diagnosis occurs. Although there might be some referral bias for patients seen in an outpatient endoscopy unit at a tertiary care institution, the broad inclusion criteria, the use of the consensus guidelines for diagnosis of EoE, and the variety of underlying causes of symptoms in the control group should make the results relatively generalizable. Th erefore, we feel that the resultant model has substantial clinical utility. It distinguishes EoE from non-EoE controls with a high degree of accuracy, and the operating characteristics of the model impact a relevant clinical decision, whether or not to obtain esophageal biopsies. Given that high costs from endoscopy and biopsy constitute a substantial portion of the overall costs of EoE patients ( 65 ) , the question of whether to biopsy has special relevance in this population. Moreover, we performed several prespecifi ed sub-analyses that show that the model performs equally well in patients with dysphagia-or GERD-predominant symptoms, as well as the subset of control patients who have elevated esophageal eosinophil counts. Finally, we also analyzed several secondary models, and when full clinical, endoscopic, and histological data are available, these models also perform very well.
In conclusion, we have performed a prospective study that validated a set of clinical and endoscopic features, including younger age, male sex, presence of dysphagia and food allergy, presence of esophageal rings, furrows, and plaques, and lack of hiatal hernia, predicts EoE with a high degree of accuracy. Using these predictors at the point-of-care to aid with clinical decision making ( https:// gicenter.med.unc.edu/cedas/eoe_clinical_calculator.html ) will avoid the eff ort and expense of low-yield histological examination for EoE and also provide guidance in cases where diff erentiating EoE from other conditions is challenging.
